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AbsTrACT
background Transthyretin-related familial amyloid 
polyneuropathy (TTR-Fap Val30Met) shows a wide 
variation in age-at-onset (aO) between generations 
and genders, as in portuguese families, where women 
display a later onset and a larger anticipation (>10 
years). Mitochondrial DNa (mtDNa) copy number was 
assessed to clarify whether it has a modifier effect on aO 
variability in portuguese patients.
Methods The mtDNa copy number of 262 samples 
(175 Val30Met TTR carriers and 87 controls (proven 
Val30Val)) was quantified by quantitative real-time pcR. 
statistical analysis was performed using IBM spss V.23 
software.
results This study shows that Val30Met TTR carriers 
have a significantly higher (p<0.001) mean mtDNa copy 
number than controls. Furthermore, the highest mtDNa 
copy number mean was observed in early-onset patients 
(aO <40 years). Importantly, early-onset offspring 
showed a significant increase (p=0.002) in the mtDNa 
copy number, when compared with their late aO parents.
Conclusions The present findings suggest, for the first 
time, that mtDNa copy number may be associated with 
earlier events and may therefore be further explored as a 
potential biomarker for follow-up of TTR-Fap Val30Met 
carriers.
INTroduCTIoN
Transthyretin-related familial amyloid polyneurop-
athy (TTR-FAP) is an autosomal dominant systemic 
amyloidosis due to point mutations in the TTR 
gene (chr18q12.1) (Online Mendelian Inheritance 
in Man, OMIM,176300), resulting in misfolded 
proteins. Although more than 100 amyloidogenic 
variants have been found in the TTR gene,1 Val30Met 
(also known as NM_000371.3:c.148G>A p.
(Val50Met)) is the most common.
FAP was classified by Andrade2 as a peculiar 
form of neuropathy and was first described in 
northern Portugal as a disease occurring between 
25 and 35 years. However, differences in mean 
age-at-onset (AO) between clusters have been 
described, including within the Portuguese popula-
tion.3–5 In TTR-FAP Val30Met Portuguese families, 
a wide AO variability (19–82 years) and AO differ-
ences between generations and genders have been 
observed.4
Recently, our group showed that anticipation 
(a decrease in AO over the generations) is a true 
biological phenomenon in TTR-FAP Val30Met.6 
Moreover, clinical differences between early-onset 
(<40 years) and late-onset (≥50 years) patients have 
also been described in other countries.7–10 Addition-
ally, in Portuguese patients, significant differences 
in AO regarding gender were confirmed, namely 
that women present a later-onset than men and 
larger anticipation (>10 years) was more frequent 
when the disease was inherited from the mothers 
(70%) than from the fathers (30%). In addition, 
mother–son pairs showed a larger anticipation, 
while father–daughter pairs showed only a residual 
anticipation.6 To clarify gender-related differences, 
we previously reported, for the first time, the 
contribution of the AR gene as an AO modifier in 
both genders.11
The mitochondrial DNA (mtDNA) is inherited 
exclusively from the mother,12 and in contrast to 
fixed diploid nuclear genome, mitochondria are 
polyploids, that is, have hundreds to several thou-
sand copies of mtDNA for each cell, depending on 
the energy demands of the tissue or the develop-
mental stage.13
The regulation of mtDNA copy number is an 
important aspect of mitochondrial genetics and 
biogenesis, essential for normal cellular function 
and crucial for maintaining cellular energy require-
ments. Thus, depletion, variation, decrease or 
excess of mtDNA copy number may be associated 
with several neurodegenerative diseases.14–16
A previous study showed that an mtDNA variant 
may explain the observed differences in penetrance 
for TTR-FAP according to the transmitting parent 
gender in Portuguese families,17 and that mtDNA 
haplogroups may be associated with AO varia-
tion in TTR-FAP Swedish and French patients.18 
However, the analysis of mtDNA copy number was 
never performed in TTR-FAP Val30Met before; 
therefore, we believe that this is a groundbreaking 
approach.
To further explore the remarkable AO variation 
between genders and especially due to the antici-
pation when the mother is the transmitting parent, 
our aim was to evaluate, for the first time, whether 




DNA samples were ascertained from Unidade 
Corino de Andrade-Centro Hospitalar do Porto 
(UCA-CHP, Porto), which has the largest database 
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of TTR-FAP Val30Met worldwide, with a registry collected 
and clinically well-characterised over 75 years. All partici-
pants signed a written informed consent. All carriers have the 
Val30Met disease-causing variant, and the AO of each patient 
has been established by the same team of neurologists, special-
ised in TTR-FAP Val30Met, when the first neuropathic symp-
toms (sensorimotor or autonomic) emerged. In the smaller 
number of cases where cardiac or kidney involvement is the sole 
symptom, their manifestation also defines onset of the disease.
We have analysed a total of 262 blood-derived DNA samples 
from 56 early-onset (<40 years) and 52 late-onset (≥40 years) 
patients, 67 asymptomatic carriers (aged ≥40 years) and 30 
non-carriers (proven Val30Val (V30V) relatives belonging to 
the same familial background). Control subjects (proven V30V) 
included blood donors, and patients’ spouses (n=57; 29 men 
and 28 women), without any TTR-FAP Val30Met familial 
history, were also enrolled in this study (table 1). DNA was 
isolated by the same method for all selected subjects. Addition-
ally, all samples were genotyped for Val30Met disease-causing 
variant and matched for the same ethnic and geographical origin 
of Portugal. All DNA samples were collected and stored at the 
Centro de Genética Preditiva e Preventiva Biobank, authorised 
by National Commission for Data Protection.
dNA extraction
Genomic DNA was extracted from peripheral blood leucocytes 
using a standard salting out method,19 according to the manufac-
turer’s instructions. Details on the method for DNA quantifica-
tion are presented as online supplementary material 1.
mtdNA extraction
The relative mtDNA copy number was measured in all samples 
using quantitative real-time PCR. This method for determining 
mtDNA copy number was detailed in a previous publication by 
Venegas and Halberg20 and was shown to have high interassay 
reliability. Details on the method for determining mtDNA copy 
number are presented as online supplementary material 1.
statistical analysis
Sample size was estimated and is in accordance with the expected 
power.
Multiple comparisons among groups were analysed by 
one-way analysis of variance (one-way ANOVA) followed by 
post-hoc corrections with Tukey HSD (honest significant differ-
ence) method.
In order to investigate the effect of mtDNA copy number in 
AO variation, a generalised estimating equations (GEE) analysis, 
to account for non-independence of AO between members of the 
same family, was performed, adjusted for gender. Evaluation of 
the parent–offspring transmissions was achieved using the t-test 
for paired samples. All statistical procedures were performed 
using the transformed variable for mtDNA copy number except 
for the initial descriptive analysis. The level of significance for 
all statistical tests was set at p<0.05. All statistical analyses were 
performed using IBM SPSS Statistics V.23 software. More details 
on statistical analysis are presented in online supplementary 
material 1.
resulTs
In table 2, we can find the descriptive analysis for mean mtDNA 
copy number for all groups studied, comprising 175 Val30Met 
TTR carriers and 87 non-carriers, in a total sample of 262 indi-
viduals of Portuguese origin. It is important to note that the 
non-transformed mean mtDNA copy number of non-carriers 
(155.21±85.23) was lower than that of Val30Met TTR carriers 
(460.11±478.91).
mtdNA copy number of peripheral blood leucocytes is 
associated with Val30Met disease-causing variant carriers
Normality of our sample was tested and the Kolmogor-
ov-Smirnov test showed that the data were not normally distrib-
uted (p<0.05).
We investigated differences in mean mtDNA copy number 
(using the transformed variable) and we found a statistically 
significant difference between groups as shown by the one-way 
ANOVA test (F (4, 257)=6.611; p<0.001). A Tukey post-hoc 
test revealed that the mtDNA copy number in controls was 
significantly lower, compared with asymptomatic carriers 
(p<0.001), late-onset patients (p=0.001) and early-onset 
patients (p<0.001). There were no statistically significant differ-
ences between the controls and non-carrier relatives (p>0.05), 
neither between non-carrier relatives and Val30Met carriers 
(p>0.05) (figure 1).
Table 1 Sample description of Val30Met TTR carriers and non-carriers
status Val30Met TTR carriers (n=175) Non-carriers (n=87)
Characteristics early-onset late-onset Asymptomatic relatives Controls Total
N 56 52 67 30 57 262
Age-at-onset, years (24–39) (40–71) na na na na
Age-at-observation, years na na (19–81) (18–76) (21–89) na
Gender
  Male 27 21 27 15 29 119
  Female 29 31 40 15 28 143
na, not applicable; TTR, transthyretin.
Table 2 Descriptive analysis of mean mtDNA copy number for all the 
groups studied
status Groups n
Mean mtdNA copy 
number/cell sd
Non-carriers Controls 57 140.19 63.11
Relatives 30 183.75 112.09
All 87 155.21 85.23
Val30Met 
TTR carriers
Asymptomatic 67 406.58 382.37
Late-onset 52 479.74 527.21
Early-onset 56 505.92 535.17
All 175 460.11 478.91
mtDNA, mitochondrial DNA; TTR, transthyretin.
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Concerning gender differences, no significant differences 
associated to mtDNA copy number were found in all groups 
studied (p>0.05; results not shown).
mtdNA copy number is not associated with Ao variation
The role of the mtDNA copy number on AO variation between 
the late-onset and early-onset patients, using GEE, did not show 
a significant effect (p>0.05; results not shown).
Variation of mtdNA content in the parent–offspring 
transmissions
Regarding parent–offspring pairs analysis, no significant differ-
ence was found between asymptomatic carriers with their 
affected parents (p>0.05), even when stratified by AO of the 
affected parents. Importantly, early-onset offspring showed a 
statistically significant increase in the mtDNA copy number, 
when compared with their late AO parents (p=0.002) (table 3).
dIsCussIoN
In the present study, mtDNA copy number was quantified in 
TTR-FAP Val30Met carriers and non-carriers to better explore 
the AO variation and its effect on gender of the transmitting 
parent and offspring, since to date a minor attention has been 
dedicated to mtDNA content in this disease. To our knowl-
edge, this is the first study that demonstrates a positive asso-
ciation between the peripheral blood mtDNA content and the 
TTR-FAP Val30Met, with implications in the underlying biolog-
ical mechanisms.
Increased mtdNA copy number in Val30Met disease-causing 
variant carriers
Comparing the different groups, we have found that the highest 
mean mtDNA copy number per cell was observed in early-onset 
patients. Moreover, subjects harbouring the Val30Met disease-
causing variant have higher mean mtDNA content than controls. 
Our results contrast with studies in other diseases, such as in 
Huntington’s21 and Parkinson’s22 diseases, in which the mtDNA 
copy number per cell declined in variant carriers compared with 
controls, possibly revealing a compensatory effect.
A previous study showed that increased cellular mtDNA copy 
number and mtDNA variants accumulated during ageing may 
be caused by oxidative stress.23 It is plausible that the increase 
Figure 1 analysis of differences in mtDNa copy number for various groups in study (non-carriers: controls and relatives; and Val30Met TTR carriers: 
asymptomatic carriers, late-onset patients and early-onset patients). asterisks (*) indicate statistical significance, p<0.05. mtDNa, mitochondrial 
DNa; TTR, transthyretin.
Table 3 Analysis of mitochondrial DNA copy number, using the transformed variable, for parent–offspring transmissions stratified by age-at-onset 
of the affected parents
Affected parent offspring n Mean sd 95% CI p Value*
Late-onset Asymptomatic 26 −162.41 508.82 [−367.93 to 43.10] 0.116
Early-onset Asymptomatic 18 −149.25 462.48 [−379.23 to 80.73] 0.189
Late-onset Early-onset 14 −307.11 293.63 [−476.64 to 137.57] 0.002
*Significance level was set to 0.05.
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in mitochondrial content in Val30Met carriers, particularly in 
early-onset patients, may be due to a compensatory response to 
maintain mitochondrial function possibly owing to decreased 
cytochrome c-oxidase (complex IV) function, as observed in 
blood cells from patients with amyotrophic lateral sclerosis.24 
Also, previous reports lead us to suggest that increased levels of 
mtDNA content, mainly in Val30Met carriers, may be related 
with higher production of reactive oxidative species (ROS), 
possibly due to the unpaired cellular processes, such as oxida-
tive stress and the presence of misfolded proteins, occurring 
in TTR-FAP Val30Met progression.25 26 It is well known that 
the functions of mitochondria and endoplasmic reticulum 
(ER) are closely linked, since both produce ROS, generated by 
products of oxidative phosphorylation27 and by unfolded-pro-
tein response.28 29 Indeed, several studies have described that 
high levels of ROS may disrupt protein folding processes, and 
increased production of misfolded proteins results in extra ER 
stress due to the accumulation of misfolded proteins, possibly 
leading to additional ROS production.29 For that reason, we 
hypothesised that an adaptation of the energetic metabolism, to 
improve mitochondrial function and cell growth,30 must have 
occurred in these patients through a compensatory mechanism, 
involving an increased ROS production and, consequently, 
energy failure. Therefore, to our knowledge, the present find-
ings revealed, for the first time, that mtDNA copy number is 
associated with earlier TTR-FAP Val30Met events.
Moreover, we found significant differences between controls 
and Val30Met carriers, suggesting that the mtDNA content is 
associated with the aetiopathogenic mechanisms of the disease. 
Interestingly, the mtDNA content is not significantly different 
neither between controls and non-carrier relatives nor between 
non-carrier relatives and Val30Met carriers, which can be due 
to a common genetic background between relatives of the same 
families besides the Val30Met disease-causing variant, showing 
that the genetic background is an important issue in studying the 
genetic modifiers of patients’ phenotype.
mtdNA content has no gender-linked effect
Regarding gender analysis, these results show that mtDNA 
content does not have a specific gender-linked effect similar to 
what was observed in other diseases,31 32 or that it is under the 
control of nuclear genes, inherited from either the mother or 
the father.
early-onset offspring have higher mtdNA copy number than 
their affected parents
The comparison of mtDNA content of late-onset offspring with 
their affected or non-affected parents could not be performed 
due to the small sample size of the parents group. Importantly, 
a higher mean mtDNA copy number was found in the early-
onset offspring when compared with their late-onset parents. 
This result suggests that early-onset offspring possibly receive 
from their affected mother a mitochondrial risk effect, modu-
lating AO.
In conclusion, this study suggests that mtDNA copy number 
seems to have a significant effect on AO variability observed in 
parent–offspring transmission. In addition, we found that mito-
chondrial gene expression is possibly associated with TTR-FAP 
Val30Met mechanisms. However, the mtDNA content is specific 
for tissue and developmental stage/age and varies according to 
the population. Therefore, it will be important to replicate this 
study in other tissues, such as liver (main organ of TTR synthesis), 
and in different populations, to unravel new clues about the 
biological mechanisms that explain the role of mitochondria 
energetic performance in processing of misfolded proteins.
Our results, although preliminary, derive from the largest 
TTR-FAP Val30Met cohort available worldwide. In addition, we 
had a special concern with the power of the statistical analyses to 
obtain accurate and reliable results.
Although further studies are required to elucidate the patho-
physiological significance of the observed changes in mitochon-
drial content in patients with TTR-FAP Val30Met, the present 
study is a step forward and opens a new possibility for elucidating 
the mechanisms underlying TTR-FAP Val30Met. mtDNA copy 
number may also be further explored as a potential biomarker 
for follow-up of TTR-FAP Val30Met carriers.
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